Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | C1S | P09871 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11422303 | 0.86 | PRSS1 (0.60) | KMT2APRSS1SMPD1NR4A2 | |
| SCHEMBL27448957 | 0.86 | NR4A2 (0.46) | KMT2ASMPD1NR4A2 | |
| SCHEMBL28858409 | 0.85 | KMT2A (0.71) | KMT2APRSS1NR4A2 | |
| SCHEMBL5499950 | 0.85 | KMT2A (0.53) | KMT2APRSS1SMPD1NR4A2F2 | |
| SCHEMBL5200730 | 0.83 | KMT2A (0.73) | KMT2ASMPD1LMNAMAPK1 | |
| SCHEMBL920108 | 0.83 | MAOB (0.60) | KMT2A | |
| SCHEMBL9565397 | 0.82 | KMT2A (0.54) | KMT2APRSS1SMPD1LMNAMAPK1 | |
| SCHEMBL5202638 | 0.82 | KMT2A (0.62) | KMT2ASMPD1LMNAMAPK1L3MBTL1 | |
| SCHEMBL30785561 | 0.82 | KMT2A (0.54) | KMT2APRSS1SMPD1LMNAMAPK1 | |
| SCHEMBL3245441 | 0.82 | KMT2A (0.50) | KMT2APRSS1SMPD1F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | KMT2A 445/4885PRSS1 4094/4885SMPD1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.